▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4060 by analyst upside · 2026-09-27
TMO
Thermo Fisher Scientific Inc.
Healthcare · Market Cap $250B · P/E 36.4x
ANALYST PRICE TARGET
-3.2%
implied upside to consensus target
Current Price $675.0
Consensus Target $653.11
Bull Target $780.0
Bear Target $520.0
Analysts Covering 27
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
19
Hold
4
Sell
0
52-Week Low $435.27
52-Week High $682.98
YTD Return +14.2%
FUNDAMENTALS
Market Cap $250B
P/E Ratio (TTM) 36.4x
Forward P/E 24.5x
EPS (TTM) $18.56
PEG Ratio 2.01
Dividend Yield 0.28%
Revenue (TTM) $46.3B
Profit Margin 15.0%
52-WEEK RANGE
52-Week Low $435.27
52-Week High $682.98
Current Price $675.0
Bear Target $520.0
Bull Target $780.0
● Now $675.0 ● Target $653.11
TRADING DATA
Avg Volume 2.1M
YTD Return +14.2%
Analyst Count 27
Consensus Buy
Upside to Target -3.2%
Last Updated 2026-09-27

ANALYST SUMMARY

Thermo Fisher Scientific Inc. (TMO) is currently trading at $675.0 with a Wall Street consensus price target of $653.11, which is 3.2% below the current price over the next 12 months. 27 analysts currently cover TMO, with a consensus rating of Buy - 85% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $780.0, while the most cautious has a target of $520.0.

TMO operates in the Healthcare sector with a market capitalisation of $250B. The stock is up 14.2% year-to-date and is currently trading near the upper end of its 52-week range of $435.27 – $682.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TMO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

CLSA ● Initiated
Outperform 2026-09-03 Building track record
Piper Sandler - Reiterated
Neutral → Neutral 2026-07-27 14% win rate (7 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-07-27 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-07-24 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-07-24 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-07-06 Building track record
Piper Sandler ● Initiated
Neutral 2026-06-11 14% win rate (7 calls)
HSBC ↓ Downgrade
Buy → Hold 2026-06-03 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
69
out of 100
Coverage depth
25/30
Consensus clarity
22/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →